Procalcitonin is a sensitive and specific marker of bacterial infection; low results allow clinicians to safely de-escalate antibiotics. This retrospective cohort study aimed to determine the effect of low procalcitonin results on withholding, discontinuing, or de-escalating antibiotics in hospitalized patients at a tertiary care center. Antibiotics were initiated or continued without de-escalation in 55% of patients with low procalcitonin results. Among patients with low procalcitonin results, the primary service, but not measures of patient complexity, disease severity, or underlying disease process (lower respiratory tract infection evaluation versus systemic inflammatory response syndrome/possible sepsis) was associated with initiation or continued broad-spectrum antibiotic use.
INTRODUCTION
Procalcitonin is highly sensitive and specific for bacterial infections [1] [2] [3] . Low procalcitonin results support clinician decisions to withhold, discontinue or de-escalate antibiotics safely, especially in the evaluation of lower respiratory tract infection or patients with systemic inflammatory response syndrome (SIRS)/possible sepsis [4] [5] [6] . International studies, largely centered in Europe, demonstrate high overall concordance between procalcitonin algorithms and antibiotic use [5, 6] . However, antibiotic use stratified by low versus high procalcitonin result is lacking, especially among hospitalized patients in the USA. This study aimed to determine the association between low procalcitonin results and withholding, discontinuation, or de-escalation of antibiotics in patients hospitalized at a US tertiary care center with an existing procalcitonin guideline.
Additionally, as procalcitonin-based algorithms are not intended to override clinical decision making by the provider, we aimed to understand better which factors may impact the decision of a provider to continue antibiotic therapy despite a low procalcitonin test result.
METHODS

Study Design and Population
This was a retrospective cohort study of all adult patients admitted to a US tertiary care center Health Information Systems, Salt Lake City, UT, USA) was used to measure disease severity, while the Charlson Comorbidity Index was used to capture patient complexity [8] . Both were calculated using billing codes (International Classification of Diseases, Ninth Revision, World Health Organization, Geneva, Switzerland).
Statistics
Descriptive statistics were used to report the proportion and means of patient-and provider-level variables. Pearson's Chi-squared test and univariate odds ratio were used to examine whether the proportion of patients receiving discordant antibiotics varied based on low versus high procalcitonin results. Among the low procalcitonin subgroup, univariate odds ratios were calculated to assess patient-and provider-level factors that may be associated with discordant antibiotic use. Multivariate modeling was attempted, but the sample size precluded an adequate mathematical fit. All statistics were calculated using STATA (ver. 12; StataCorp LP, College Station, TX, USA).
RESULTS
All 181 hospitalized patients who underwent procalcitonin testing during the 2-month study period were included in the analysis, and cohort characteristics are presented in Table 1 . Half of them (n = 91) had low procalcitonin levels. The Among patients with low procalcitonin results, provider-but not patient-level factors were statistically significant in the univariate analysis. In this subgroup, critical care services were more likely than medicine teams to use antibiotics discordantly (OR 4.43, p = 0.011, Table 1 ). Immunocompromised services were also more likely than medicine services to use antibiotics discordantly in patients with low A limitation in the current study was the inability to analyze serial procalcitonin measurements, which are commonly performed in septic patients, on concordance. In our data set, there were less than ten patients who had serial measurements and all had initial high procalcitonin levels.
DISCUSSION
The effectiveness of low procalcitonin results to encourage physicians to withhold, de-escalate, or discontinue antibiotics in this retrospective study at a US tertiary care center is lower than the efficacy reported in predominantly European clinical trials [5, 6] . Antibiotics were held, stopped, or de-escalated in less than half of the patients with low procalcitonin levels (\0.25 ng/mL), despite its excellent negative predictive value. Positive cultures could only account for a small proportion of this discrepancy. Although our overall concordance rate was on par with prior studies, this value is strongly skewed by very high concordance in patients with elevated Provider-level factors, rather than disease severity or patient complexity, may be an important variable in the initiation or continued use of broad-spectrum antibiotics for patients with low procalcitonin levels.
CONCLUSION
Less than 50% of inpatients with a low procalcitonin result had their antibiotics held, de-escalated, or discontinued despite its excellent negative predictive value. Our study suggests an important area for continued research on antimicrobial prescribing practices, and improved antibiotic stewardship using procalcitonin should include the use of behavioral sciences approaches, for example social psychology and behavioral economic principles [9] [10] [11] , in addition to traditional stewardship interventions such as direct oversight using prospective audit and feedback by an antibiotic stewardship team [12] [13] [14] .
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